{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:34:03Z","timestamp":1787585643273,"version":"build-2736575974"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"DOI":"10.1007\/s13304-026-02823-3","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:55:24Z","timestamp":1787579724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy in colorectal cancer: redefining surgical decision-making"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-1783","authenticated-orcid":false,"given":"Emanuele","family":"Rausa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"De Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aiolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vitellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"3","key":"2823_CR1","first-page":"145","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70(3):145\u2013164","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2823_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2823_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T et al (2020) Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(10):1291\u20131305","journal-title":"Ann Oncol"},{"issue":"3","key":"2823_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cgh.2022.12.008","volume":"21","author":"M Hanna","year":"2023","unstructured":"Hanna M, Dey N, Grady WM (2023) Emerging tests for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol 21(3):604\u2013616","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2823_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J et al (2024) Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther 9(1):336","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2823_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2025","unstructured":"Pantel K, Alix-Panabi\u00e8res C (2025) Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol 22(1):65\u201377","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2823_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2018.07.017","volume":"155","author":"TR Levin","year":"2018","unstructured":"Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG et al (2018) Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology 155(5):1383\u201391.e5","journal-title":"Gastroenterology"},{"issue":"8","key":"2823_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41575-022-00612-y","volume":"19","author":"A Shaukat","year":"2022","unstructured":"Shaukat A, Levin TR (2022) Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol 19(8):521\u2013531","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"18","key":"2823_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1001\/jama.2023.22231","volume":"330","author":"EK Barnell","year":"2023","unstructured":"Barnell EK, Wurtzler EM, La Rocca J, Fitzgerald T, Petrone J, Hao Y et al (2023) Multitarget stool RNA test for colorectal cancer screening. JAMA 330(18):1760\u20131768","journal-title":"JAMA"},{"issue":"14","key":"2823_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","volume":"370","author":"TF Imperiale","year":"2014","unstructured":"Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP et al (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"1","key":"2823_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53711-3","volume":"9","author":"H Osumi","year":"2019","unstructured":"Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H (2019) Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci Rep 9(1):17358","journal-title":"Sci Rep"},{"key":"2823_CR12","doi-asserted-by":"crossref","unstructured":"Frountzas M (2025) New insights into personalized surgical oncology. J Pers Med 15","DOI":"10.3390\/jpm15070295"},{"key":"2823_CR13","doi-asserted-by":"crossref","unstructured":"Savino FD, Rigali F, Giustini V, D'Aliberti D, Spinelli S, Piazza R et al (2022) Liquid biopsy in cancer: focus on lymphoproliferative disorders. Cancers (Basel) 14(21)","DOI":"10.3390\/cancers14215378"},{"issue":"1","key":"2823_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15(1):131","journal-title":"J Hematol Oncol"},{"issue":"36","key":"2823_CR15","doi-asserted-by":"publisher","first-page":"24514","DOI":"10.18632\/oncotarget.25314","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Shi XQ, Zeng PW, Mo FM, Chen ZH (2018) Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis. Oncotarget 9(36):24514\u201324524","journal-title":"Oncotarget"},{"issue":"10","key":"2823_CR16","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/1878-0261.12942","volume":"15","author":"X Wu","year":"2021","unstructured":"Wu X, Zhang Y, Hu T, He X, Zou Y, Deng Q et al (2021) A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol Oncol 15(10):2702\u20132714","journal-title":"Mol Oncol"},{"issue":"8","key":"2823_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H et al (2019) Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5(8):1124\u20131131","journal-title":"JAMA Oncol"},{"issue":"6","key":"2823_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252897","volume":"16","author":"TSA Abdalla","year":"2021","unstructured":"Abdalla TSA, Meiners J, Riethdorf S, K\u00f6nig A, Melling N, Gorges T et al (2021) Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. PLoS ONE 16(6):e0252897","journal-title":"PLoS ONE"},{"issue":"12","key":"2823_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.5306\/wjco.v12.i12.1169","volume":"12","author":"A Yadav","year":"2021","unstructured":"Yadav A, Kumar A, Siddiqui MH (2021) Detection of circulating tumour cells in colorectal cancer: emerging techniques and clinical implications. World J Clin Oncol 12(12):1169\u20131181","journal-title":"World J Clin Oncol"},{"issue":"21","key":"2823_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113582","volume":"23","author":"J Petrik","year":"2022","unstructured":"Petrik J, Verbanac D, Fabijanec M, Hulina-Toma\u0161kovi\u0107 A, \u010ceri A, Somborac-Ba\u010dura A, Petlevski R, Grdi\u0107 Rajkovi\u0107 M, Rumora L, Kru\u0161lin B, \u0160tefanovi\u0107 M, Ljubi\u010di\u0107 N, Bar\u0161i\u0107 N, Han\u017eek A, Bo\u010dkor L, \u0106elap I, Demirovi\u0107 A, Bari\u0161i\u0107 K (2022) Circulating tumor cells in colorectal cancer: detection systems and clinical utility. Int J Mol Sci 23(21):13582","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2823_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","volume":"31","author":"TV Henriksen","year":"2025","unstructured":"Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH et al (2025) Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer. Clin Cancer Res 31(9):1676\u20131685","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2823_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","volume":"25","author":"CM Lockwood","year":"2023","unstructured":"Lockwood CM, Borsu L, Cankovic M, Earle JSL, Gocke CD, Hameed M et al (2023) Recommendations for cell-free DNA assay validations: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn 25(12):876\u2013897","journal-title":"J Mol Diagn"},{"issue":"1","key":"2823_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","volume":"70","author":"P van der Leest","year":"2024","unstructured":"van der Leest P, Schuuring E (2024) Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling. Clin Chem 70(1):220\u2013233","journal-title":"Clin Chem"},{"issue":"1","key":"2823_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12672-024-01481-4","volume":"15","author":"JS Park","year":"2024","unstructured":"Park JS, Choi JA, Hyun DH, Byeon C, Kwak SG, Hong S (2024) Revisiting the diagnostic performance of exosomes: harnessing the feasibility of combinatorial exosomal miRNA profiles for colorectal cancer diagnosis. Discov Oncol 15(1):605","journal-title":"Discov Oncol"},{"key":"2823_CR25","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.csbj.2024.05.011","volume":"23","author":"J Li","year":"2024","unstructured":"Li J, Tian J, Liu Y, Liu Z, Tong M (2024) Personalized analysis of human cancer multi-omics for precision oncology. Comput Struct Biotechnol J 23:2049\u20132056","journal-title":"Comput Struct Biotechnol J"},{"key":"2823_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143600","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Janku F, Kurzrock R (2021) Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13143600","journal-title":"Cancers (Basel)"},{"key":"2823_CR27","doi-asserted-by":"publisher","first-page":"1002333","DOI":"10.37349\/etat.2025.1002333","volume":"6","author":"ES Kuligina","year":"2025","unstructured":"Kuligina ES, Yanus GA, Imyanitov EN (2025) Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives. Explor Target Antitumor Ther 6:1002333","journal-title":"Explor Target Antitumor Ther"},{"issue":"14","key":"2823_CR28","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1158\/1078-0432.CCR-23-3660","volume":"30","author":"AR Parikh","year":"2024","unstructured":"Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA et al (2024) Minimal residual disease using a plasma-only circulating tumor DNA assay to predict recurrence of metastatic colorectal cancer following curative intent treatment. Clin Cancer Res 30(14):2964\u20132973","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2823_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40291-021-00559-x","volume":"25","author":"K Chen","year":"2021","unstructured":"Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA et al (2021) Commercial ctDNA assays for minimal residual disease detection of solid tumors. Mol Diagn Ther 25(6):757\u2013774","journal-title":"Mol Diagn Ther"},{"key":"2823_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102821","volume":"130","author":"A Gandini","year":"2024","unstructured":"Gandini A, Taieb J, Blons H, Netter J, Laurent-Puig P, Gallois C (2024) Early-onset colorectal cancer: from the laboratory to the clinic. Cancer Treat Rev 130:102821","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2823_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, Jerobin J, Altemani FH et al (2024) Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther 9(1):27","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 8","key":"2823_CR32","doi-asserted-by":"publisher","first-page":"S1316","DOI":"10.21037\/tcr.2017.08.13","volume":"6","author":"ER Sauter","year":"2017","unstructured":"Sauter ER (2017) Exosomes in blood and cancer. Transl Cancer Res 6(Suppl 8):S1316\u2013S1320","journal-title":"Transl Cancer Res"},{"issue":"7","key":"2823_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105491","volume":"10","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello D, Boscolo Bielo L, Pietrantonio F, Martini G, Troiani T, Martinelli E et al (2025) Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial. ESMO Open 10(7):105491","journal-title":"ESMO Open"},{"issue":"1","key":"2823_CR34","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams WT, Mackay M, Ben-Shachar R, Drews J, Manghnani K, Hockenberry AJ et al (2024) Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open 7(1):e2351700","journal-title":"JAMA Netw Open"},{"key":"2823_CR35","unstructured":"https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1428"},{"issue":"1","key":"2823_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02063-2","volume":"23","author":"XY Tao","year":"2024","unstructured":"Tao XY, Li QQ, Zeng Y (2024) Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring. Mol Cancer 23(1):145","journal-title":"Mol Cancer"},{"issue":"3","key":"2823_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10620-015-3600-5","volume":"60","author":"AG Zauber","year":"2015","unstructured":"Zauber AG (2015) The impact of screening on colorectal cancer mortality and incidence: Has it really made a difference? Dig Dis Sci 60(3):681\u2013691","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2823_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40291-020-00473-8","volume":"24","author":"M Shirley","year":"2020","unstructured":"Shirley M (2020) Epi proColon(\u00ae) for colorectal cancer screening: a profile of its use in the USA. Mol Diagn Ther 24(4):497\u2013503","journal-title":"Mol Diagn Ther"},{"key":"2823_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157619","author":"P Ziranu","year":"2025","unstructured":"Ziranu P, Pretta A, Saba G, Spanu D, Donisi C, Ferrari PA et al (2025) Navigating the landscape of liquid biopsy in colorectal cancer: current insights and future directions. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26157619","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2823_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C et al (2024) A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med 390(11):973\u2013983","journal-title":"N Engl J Med"},{"issue":"2","key":"2823_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","volume":"63","author":"TR Church","year":"2014","unstructured":"Church TR et al (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2):317\u2013325","journal-title":"Gut"},{"issue":"1","key":"2823_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamasurg.2023.5394","volume":"159","author":"KM Mahuron","year":"2024","unstructured":"Mahuron KM, Fong Y (2024) Applications of liquid biopsy for surgical patients with cancer: a review. JAMA Surg 159(1):96\u2013103","journal-title":"JAMA Surg"},{"key":"2823_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.826785","volume":"13","author":"S Zha","year":"2022","unstructured":"Zha S, Li T, Zheng Q, Li L (2022) Whether patients with stage \u2161\/\u2162 colorectal cancer benefit from adjuvant chemotherapy: a modeling analysis of literature aggregate data. Front Pharmacol 13:826785","journal-title":"Front Pharmacol"},{"issue":"9","key":"2823_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047831","volume":"11","author":"PM Kasi","year":"2021","unstructured":"Kasi PM, Sawyer S, Guilford J, Munro M, Ellers S, Wulff J et al (2021) BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open 11(9):e047831","journal-title":"BMJ Open"},{"issue":"1","key":"2823_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H et al (2023) Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29(1):127\u2013134","journal-title":"Nat Med"},{"key":"2823_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.004","volume":"159","author":"L Benhaim","year":"2021","unstructured":"Benhaim L, Bouch\u00e9 O, Normand C, Didelot A, Mulot C, Le Corre D et al (2021) Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Eur J Cancer 159:24\u201333","journal-title":"Eur J Cancer"},{"issue":"5","key":"2823_CR47","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R et al (2025) Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med 31(5):1509\u20131518","journal-title":"Nat Med"},{"issue":"12","key":"2823_CR48","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T et al (2025) Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med 31(12):4291\u20134300","journal-title":"Nat Med"},{"key":"2823_CR49","doi-asserted-by":"crossref","unstructured":"Lonardi S, Pietrantonio F, Tarazona Llavero N, Montagut Viladot C, Sartore Bianchi A, Zampino MG The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. ESMO 2023 S1268-S1269October 2023","DOI":"10.1016\/j.annonc.2023.10.020"},{"key":"2823_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.5","author":"VK Morris","year":"2024","unstructured":"Morris VK, Yothers G, Kopetz S, Puhalla SL, Lucas PC, Iqbal A (2024) Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II\/ III study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.5","journal-title":"J Clin Oncol"},{"key":"2823_CR51","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03748680"},{"key":"2823_CR52","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04089631"},{"key":"2823_CR53","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000507-20\/ES"},{"key":"2823_CR54","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05174169"},{"key":"2823_CR55","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05062889"},{"key":"2823_CR56","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05427669"},{"key":"2823_CR57","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04050345"},{"issue":"8","key":"2823_CR58","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/1878-0261.12729","volume":"14","author":"TV Henriksen","year":"2020","unstructured":"Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtr\u00f6der K, G\u00f6genur M et al (2020) The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol 14(8):1670\u20131679","journal-title":"Mol Oncol"},{"key":"2823_CR59","unstructured":"Rubio-Alarc\u00f3n C, Georgiadis A, Franken IA, Wang H, van Nassau S, Schraa SJ, et al. (2025) Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study. Br J Surg 113(1)"},{"key":"2823_CR60","volume":"59","author":"E Sanderson","year":"2025","unstructured":"Sanderson E, Gibbs P, Tie J (2025) The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. Lancet Reg Health West Pac 59:101595","journal-title":"Lancet Reg Health West Pac"},{"issue":"6","key":"2823_CR61","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","volume":"9","author":"S Mo","year":"2023","unstructured":"Mo S, Ye L, Wang D, Han L, Zhou S, Wang H et al (2023) Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol 9(6):770\u2013778","journal-title":"JAMA Oncol"},{"issue":"24","key":"2823_CR62","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-25-1242","volume":"31","author":"T Akiyoshi","year":"2025","unstructured":"Akiyoshi T, Shinozaki E, Maeda Y, Taguchi S, Chino A, Hanaoka Y et al (2025) CtDNA longitudinal analysis during total neoadjuvant therapy and nonoperative management for locally advanced rectal cancer: a biomarker study from the NOMINATE trial. Clin Cancer Res 31(24):5188\u20135197","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2823_CR63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00384-024-04656-1","volume":"39","author":"NJ O'Sullivan","year":"2024","unstructured":"O\u2019Sullivan NJ, Temperley HC, Kyle ET, Sweeney KJ, O\u2019Neill M, Gilham C et al (2024) Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 39(1):82","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"2823_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41698-025-01208-w","volume":"10","author":"P Manca","year":"2025","unstructured":"Manca P, Chen CT, Shah F, Lee C, Domenico D, Omer D et al (2025) Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer. NPJ Precis Oncol 10(1):8","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"2823_CR65","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S1470-2045(25)00542-X","volume":"26","author":"A Amatu","year":"2025","unstructured":"Amatu A, Patelli G, Zampino MG, Bergamo F, Mosconi S, Tosi F et al (2025) Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial. Lancet Oncol 26(12):1612\u20131625","journal-title":"Lancet Oncol"},{"issue":"5","key":"2823_CR66","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702\u2013715","journal-title":"Lancet Oncol"},{"issue":"1","key":"2823_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02415-y","volume":"19","author":"G Yu","year":"2021","unstructured":"Yu G, Lu W, Jiao Z, Qiao J, Ma S, Liu X (2021) A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy. World J Surg Oncol 19(1):305","journal-title":"World J Surg Oncol"},{"key":"2823_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152560","author":"JK Kim","year":"2025","unstructured":"Kim JK, Alden AJ, Knaus S, Thakkar R, Moudgill L, Chudzinski A et al (2025) Circulating tumor DNA detects minimal residual disease in patients with locally advanced rectal cancer after total neoadjuvant therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17152560","journal-title":"Cancers (Basel)"},{"key":"2823_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf354","author":"G Brar","year":"2025","unstructured":"Brar G, Kasi PM (2025) The utility of ctDNA in rectal cancer. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf354","journal-title":"Oncologist"},{"key":"2823_CR70","unstructured":"Cohen JD et al. (2024) Peter gibbs circulating, advanced tDaiacil, rectal cancer: the randomized AGITG DYNAMIC-rectal study. J Clin Oncol 42:3_suppl"},{"key":"2823_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241249602","volume":"16","author":"L Gervaso","year":"2024","unstructured":"Gervaso L, Ciardiello D, Gregato G, Guidi L, Valenza C, Ascione L et al (2024) Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment. Ther Adv Med Oncol 16:17588359241249602","journal-title":"Ther Adv Med Oncol"},{"key":"2823_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051473","author":"S Udagawa","year":"2023","unstructured":"Udagawa S, Ooki A, Shinozaki E, Fukuda K, Yamaguchi K, Osumi H (2023) Circulating tumor DNA: the dawn of a new era in the optimization of chemotherapeutic strategies for metastatic colo-rectal cancer focusing on RAS mutation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15051473","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2823_CR73","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41416-022-01769-8","volume":"127","author":"G Mauri","year":"2022","unstructured":"Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S et al (2022) Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 127(3):394\u2013407","journal-title":"Br J Cancer"},{"key":"2823_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1069370","volume":"13","author":"G Martini","year":"2023","unstructured":"Martini G, Ciardiello D, Napolitano S, Martinelli E, Troiani T, Latiano TP et al (2023) Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS\/BRAF wild type tumors at start of first line: the CAPRI 2 GOIM trial. Front Oncol 13:1069370","journal-title":"Front Oncol"},{"issue":"4","key":"2823_CR75","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang S, Woo S, Kang B, Kang H, Kim JS, Lee SH et al (2025) Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol 82(4):649\u2013657","journal-title":"J Hepatol"},{"issue":"12","key":"2823_CR76","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.annonc.2024.08.2334","volume":"35","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A et al (2024) Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS\/BRAF(V600E) wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Ann Oncol 35(12):1105\u20131115","journal-title":"Ann Oncol"},{"key":"2823_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115642","volume":"226","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello D, Boscolo Bielo L, Napolitano S, Cioli E, Latiano TP, De Stefano A et al (2025) Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: findings from the CAPRI-2 GOIM study. Eur J Cancer 226:115642","journal-title":"Eur J Cancer"},{"issue":"4","key":"2823_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5635","volume":"7","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G et al (2024) Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial. JAMA Netw Open 7(4):e245635","journal-title":"JAMA Netw Open"},{"key":"2823_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081941","author":"D Ciardiello","year":"2021","unstructured":"Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T et al (2021) Biomarker-guided anti-EGFR rechallenge therapy in metastatic colorectal cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081941","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2823_CR80","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/annonc\/mdy509","volume":"30","author":"CM Parseghian","year":"2019","unstructured":"Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S et al (2019) Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 30(2):243\u2013249","journal-title":"Ann Oncol"},{"issue":"8","key":"2823_CR81","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G et al (2022) Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 28(8):1612\u20131618","journal-title":"Nat Med"},{"issue":"7","key":"2823_CR82","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795\u2013801","journal-title":"Nat Med"},{"issue":"3","key":"2823_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell\u2019Aquila E, Lonardi S, Conca E, Del Re M et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 5(3):343\u2013350","journal-title":"JAMA Oncol"},{"issue":"3","key":"2823_CR84","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N et al (2024) Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann Oncol 35(3):267\u2013275","journal-title":"Ann Oncol"},{"issue":"11","key":"2823_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285580","volume":"18","author":"A Runkel","year":"2023","unstructured":"Runkel A, Braig D, Bogner B, Schmid A, Lausch U, Boneberg A et al (2023) Non-invasive monitoring of neoadjuvant radiation therapy response in soft tissue sarcomas by multiparametric MRI and quantification of circulating tumor DNA-A study protocol. PLoS ONE 18(11):e0285580","journal-title":"PLoS ONE"},{"issue":"16","key":"2823_CR86","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1158\/1078-0432.CCR-17-0232","volume":"23","author":"AR Thierry","year":"2017","unstructured":"Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM et al (2017) Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin Cancer Res 23(16):4578\u20134591","journal-title":"Clin Cancer Res"},{"key":"2823_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104947","volume":"216","author":"M Ansab","year":"2025","unstructured":"Ansab M, Rath S, Araib E, Ishaque G, Ramzan NUH, Qasim SA et al (2025) Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 216:104947","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2823_CR88","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41(3):678\u2013700","journal-title":"J Clin Oncol"},{"key":"2823_CR89","doi-asserted-by":"crossref","unstructured":"Jun Watanabe MK et al. (2025) A randomized, double-blind, phase III study comparing trifluridine\/tipiracil (FTD\/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study. Cancer Res 85(8_Supplement_2):CT131","DOI":"10.1158\/1538-7445.AM2025-CT131"},{"issue":"12","key":"2823_CR90","doi-asserted-by":"publisher","first-page":"e2452661","DOI":"10.1001\/jamanetworkopen.2024.52661","volume":"7","author":"J Ji","year":"2024","unstructured":"Ji J, Wang C, Goel A, Melstrom K, Zerhouni Y, Lai L et al (2024) Circulating tumor DNA testing in curatively resected colorectal cancer and salvage resection. JAMA Netw Open 7(12):e2452661","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2823_CR91","doi-asserted-by":"publisher","first-page":"e221093","DOI":"10.1001\/jamanetworkopen.2022.1093","volume":"5","author":"M Fakih","year":"2022","unstructured":"Fakih M, Sandhu J, Wang C, Kim J, Chen YJ, Lai L et al (2022) Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and carcinoembryonic antigen levels in patients with resected colorectal cancer. JAMA Netw Open 5(3):e221093","journal-title":"JAMA Netw Open"},{"key":"2823_CR92","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05904665"},{"key":"2823_CR93","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05161585"},{"key":"2823_CR94","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04084249"},{"issue":"10","key":"2823_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71409","volume":"8","author":"M Mohiuddin","year":"2025","unstructured":"Mohiuddin M (2025) Monitoring and assessment of circulating tumor DNA in cancers using ultrarapid sensitivity as an innovative practice. Health Sci Rep 8(10):e71409","journal-title":"Health Sci Rep"},{"issue":"14","key":"2823_CR96","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.ejca.2014.06.020","volume":"50","author":"LM Wiltink","year":"2014","unstructured":"Wiltink LM, Chen TY, Nout RA, Kranenbarg EM, Fiocco M, Laurberg S et al (2014) Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer 50(14):2390\u20132398","journal-title":"Eur J Cancer"},{"issue":"1","key":"2823_CR97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.21037\/jgo.2019.10.03","volume":"11","author":"D Fern\u00e1ndez-Mart\u00ednez","year":"2020","unstructured":"Fern\u00e1ndez-Mart\u00ednez D, Rodr\u00edguez-Infante A, Otero-D\u00edez JL, Baldonedo-Cernuda RF, Mosteiro-D\u00edaz MP, Garc\u00eda-Fl\u00f3rez LJ (2020) Is my life going to change?-a review of quality of life after rectal resection. J Gastrointest Oncol 11(1):91\u2013101","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2823_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40364-025-00796-w","volume":"13","author":"D Ma","year":"2025","unstructured":"Ma D, Gao X, Wang L, Yin H, Feng L, Zhu Y (2025) Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications. Biomark Res 13(1):89","journal-title":"Biomark Res"},{"issue":"1","key":"2823_CR99","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/annonc\/mdx650","volume":"29","author":"AR Parikh","year":"2018","unstructured":"Parikh AR, Corcoran RB (2018) Monitoring resistance through liquid biopsy. Ann Oncol 29(1):8\u201311","journal-title":"Ann Oncol"},{"key":"2823_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115013","author":"CA Coppola","year":"2025","unstructured":"Coppola CA, De Summa S, Matera G, Pilato B, Traversa D, Tommasi S (2025) Liquid biopsy: the challenges of a revolutionary approach in oncology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26115013","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2823_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70243","volume":"6","author":"T Wolde","year":"2020","unstructured":"Wolde T, Bhardwaj V, Pandey V (2020) Current bioinformatics tools in precision oncology. MedComm (Beijing) 6(7):e70243","journal-title":"MedComm (Beijing)"},{"key":"2823_CR102","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04920032"},{"key":"2823_CR103","doi-asserted-by":"crossref","unstructured":"Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K et al. The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies? Transl Gastroenterol Hepatol 11:China2026. 2.","DOI":"10.21037\/tgh-25-75"},{"issue":"11","key":"2823_CR104","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/1878-0261.13557","volume":"18","author":"E Kalashnikova","year":"2024","unstructured":"Kalashnikova E, Aushev VN, Malashevich AK, Tin A, Krinshpun S, Salari R et al (2024) Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors. Mol Oncol 18(11):2649\u20132657","journal-title":"Mol Oncol"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02823-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02823-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02823-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:11:04Z","timestamp":1787584264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02823-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":104,"alternative-id":["2823"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02823-3","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the patients enrolled in the study signed the informed consent statement.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}